Medication info
Klerato 5 mg (Rosuvastatin Calcium)

Klerato 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201901008 · Approved 2019.02.19 · Insurance code 670501320

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goals for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and reduction of cardiovascular disease risk

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • dyslipidemia type familial
  • increased LDL-cholesterol
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol level
  • smoking
View approved original text

This medication is used as an adjunct treatment for patients with primary hypercholesterolemia and mixed hyperlipidemia when they are not adequately controlled by diet and exercise. It is also used in conjunction with other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia to enhance therapeutic effects. For patients with hypercholesterolemia, it helps lower total cholesterol and LDL-cholesterol levels to target levels, delaying the progression of atherosclerosis. It effectively reduces LDL-cholesterol and related markers as an adjunct to diet in patients with heterozygous familial hypercholesterolemia, particularly in children and adolescents. Additionally, it serves as an adjunct in patients with primary dysbetalipoproteinemia. Lastly, it contributes to reducing the risk of cardiovascular diseases in men aged over 50 and women aged over 60 with specific conditions. This medication is effectively used to improve various conditions related to hyperlipidemia.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 mg once daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: Systemic exposure to rosuvastatin was not increased in patients with a Child-Pugh score of 7 or less, but was increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years) The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goals for each patient. The dose should be adjusted at intervals of 4 weeks or longer. The safety and efficacy in children under 10 years of age have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be administered to patients who are allergic to this drug, those with severe liver dysfunction, patients with muscle diseases, and those with certain kidney disorders. Women who are pregnant or breastfeeding, or those who may become pregnant and are not using appropriate contraception, should not use this medication. Caution is particularly warranted for patients at risk of muscle damage. Symptoms such as muscle pain, muscle weakness, and in severe cases, rhabdomyolysis may occur, so if such symptoms arise, healthcare professionals should be immediately notified. There may be liver function abnormalities; therefore, regular liver function tests should be conducted before and during treatment. Excessive alcohol consumption or a history of liver disease while taking this medication requires caution. Patients with conditions such as hypothyroidism or nephrotic syndrome should first receive treatment for the underlying condition before using this medication. This medication may elevate blood sugar levels or increase the risk of developing diabetes in some patients; therefore, regular monitoring of blood sugar levels is necessary for patients requiring blood sugar management. Serious side effects such as interstitial lung disease and severe skin reactions (e.g., Stevens-Johnson syndrome) have been rarely reported; if symptoms like difficulty breathing, rash, or severe itching occur, immediate consultation with a doctor is necessary. There may be interactions when taking this medication alongside other drugs, so it is crucial to inform healthcare providers or pharmacists of any medications currently being taken. Exercise particular caution when taken with drugs that may increase the risk of muscle damage. Pregnant or breastfeeding women should not use this medication, and women who could become pregnant should use appropriate contraception. In case of an overdose, there is no specific antidote, so immediate hospital treatment must be sought, and liver function and muscle enzyme levels should be monitored. Dizziness may occur during the course of treatment, therefore care should be taken when driving or operating machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from exposure to air and moisture. It is important to maintain the storage temperature between 1°C and 30°C to preserve the medication's efficacy and prevent deterioration.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.